Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Clarifies Conditions for Mixing, Diluting or Repackaging Biologics

  • Post author:Sam
  • Post published:January 22, 2018
  • Post category:Drug Industry Daily

The FDA issued a final guidance on approved biologics that are mixed, diluted or repackaged, noting when the agency will not take action against violations of its standard rules on…

Continue ReadingFDA Clarifies Conditions for Mixing, Diluting or Repackaging Biologics

Appeals Court Upholds Dismissal of Pfizer Testosterone Lawsuits, Citing FD&C Preemption

  • Post author:Sam
  • Post published:January 22, 2018
  • Post category:Drug Industry Daily

The Seventh Circuit Court of Appeals in Chicago declined to revive several lawsuits against Pfizer over its testosterone drug Depo-T that had previously been among thousands of complaints in multidistrict…

Continue ReadingAppeals Court Upholds Dismissal of Pfizer Testosterone Lawsuits, Citing FD&C Preemption

Deal Spree Continues as Celgene Nabs Juno in $9B Deal

  • Post author:Sam
  • Post published:January 21, 2018
  • Post category:BioPharma

The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace

Continue ReadingDeal Spree Continues as Celgene Nabs Juno in $9B Deal

Hepatares Co-Founder to Helm Merck's New R&D Center in the UK

  • Post author:Sam
  • Post published:January 21, 2018
  • Post category:BioPharma

Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015. Source: BioSpace

Continue ReadingHepatares Co-Founder to Helm Merck's New R&D Center in the UK

Most-Wanted Life Sciences Employers in Genetown

  • Post author:Sam
  • Post published:January 21, 2018
  • Post category:BioPharma

Life sciences professionals don't have to look far for opportunity in Genetown. Source: BioSpace

Continue ReadingMost-Wanted Life Sciences Employers in Genetown

Bay Area's Adamas Pharma Pays Big Bucks to Double HQ

  • Post author:Sam
  • Post published:January 21, 2018
  • Post category:BioPharma

With the commercial launch of newly-approved Parkinson's disease treatment Gocovri, Bay Area drugmaker Adamas is growing. Source: BioSpace

Continue ReadingBay Area's Adamas Pharma Pays Big Bucks to Double HQ

Idera, Biocryst Tie the Knot and Transform Into a Rare Disease Pharma

  • Post author:Sam
  • Post published:January 21, 2018
  • Post category:BioPharma

The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of Idera, who will also serve as a member of the Board. Source: BioSpace

Continue ReadingIdera, Biocryst Tie the Knot and Transform Into a Rare Disease Pharma

What You Need to Know About Indalo Therapeutics

  • Post author:Sam
  • Post published:January 21, 2018
  • Post category:BioPharma

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. Source: BioSpace

Continue ReadingWhat You Need to Know About Indalo Therapeutics

Bay Area's Eureka Therapeutics Banks $60M

  • Post author:Sam
  • Post published:January 21, 2018
  • Post category:BioPharma

Acorn Pacific Ventures led the round, with participation from GP Capital and all existing major investors. Source: BioSpace

Continue ReadingBay Area's Eureka Therapeutics Banks $60M

Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ

  • Post author:Sam
  • Post published:January 21, 2018
  • Post category:BioPharma

The deal has Sanofi paying $105 per share in cash. Source: BioSpace

Continue ReadingSanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ
  • Go to the previous page
  • 1
  • …
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.